These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 1979168)

  • 21. Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen.
    Cheng SH; Espino PC; Marshall J; Harvey R; Merrill J; Smith AE
    J Virol; 1991 Jan; 65(1):170-9. PubMed ID: 1985196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene.
    Lev S; Yarden Y; Givol D
    Mol Cell Biol; 1990 Nov; 10(11):6064-8. PubMed ID: 1700279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics.
    Nair N; Davis RJ; Robinson HL
    Mol Cell Biol; 1992 May; 12(5):2010-6. PubMed ID: 1314948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The amino-terminal region of pp60c-src has a modulatory role and contains multiple sites of tyrosine phosphorylation.
    Espino PC; Harvey R; Schweickhardt RL; White GA; Smith AE; Cheng SH
    Oncogene; 1990 Mar; 5(3):283-93. PubMed ID: 1690377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
    Connelly PA; Stern DF
    Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF; Heffernan PA; Weinberg RA
    Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A chimeric, ligand-binding v-erbB/EGF receptor retains transforming potential.
    Riedel H; Schlessinger J; Ullrich A
    Science; 1987 Apr; 236(4798):197-200. PubMed ID: 3494307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2.
    Di Fiore PP; Helin K; Kraus MH; Pierce JH; Artrip J; Segatto O; Bottaro DP
    EMBO J; 1992 Nov; 11(11):3927-33. PubMed ID: 1356764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site.
    Theroux SJ; Taglienti-Sian C; Nair N; Countaway JL; Robinson HL; Davis RJ
    J Biol Chem; 1992 Apr; 267(12):7967-70. PubMed ID: 1349014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning, expression, and biological effects of erbB-2/neu gene in mammalian cells.
    Di Fiore PP; Segatto O; Aaronson SA
    Methods Enzymol; 1991; 198():272-7. PubMed ID: 1677443
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of autophosphorylation in modulation of erbB-2 transforming function.
    Segatto O; Lonardo F; Pierce JH; Bottaro DP; Di Fiore PP
    New Biol; 1990 Feb; 2(2):187-95. PubMed ID: 1982072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
    Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation.
    Massoglia S; Gray A; Dull TJ; Munemitsu S; Kun HJ; Schlessinger J; Ullrich A
    Mol Cell Biol; 1990 Jun; 10(6):3048-55. PubMed ID: 1971419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of a tyrosine-specific protein kinase activity associated with the retroviral erbB oncogene product.
    Heimann B; Beimling P; Pfaff E; Schaller H; Moelling K
    Exp Cell Res; 1985 Nov; 161(1):199-208. PubMed ID: 2996915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cloning and activation of the Syrian hamster neu proto-oncogene.
    Nakamura T; Ushijima T; Ishizaka Y; Nagao M; Arai M; Yamazaki Y; Ishikawa T
    Gene; 1994 Mar; 140(2):251-5. PubMed ID: 7908275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
    Mitra G
    Oncogene; 1991 Dec; 6(12):2237-41. PubMed ID: 1837350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.
    Semba K; Kamata N; Toyoshima K; Yamamoto T
    Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6497-501. PubMed ID: 2995967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ; Maihle NJ
    Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.